Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte Autran

Showing results (111-120 of 201) with videos related to

Pageof 21
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2008
Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activationValérie Martinez, Marie-Claude Diemert, Martine Braibant, et al.
AIDS (London, England)|October 22, 2010
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patientsAna Canestri, Anne Krivine, Lambert Assoumou, et al.
AIDS (London, England)|April 8, 2009
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patientsAntoine Bénard, Florence Damond, Pauline Campa, et al.
AIDS (London, England)|May 12, 2017
Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individualsMorgane Griesbeck, Marc-Antoine Valantin, Karine Lacombe, et al.
AIDS Research and Human Retroviruses|October 14, 2020
A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected NonprogressorsMariama Sadjo Diallo, Assia Samri, Charlotte Charpentier, et al.
AIDS (London, England)|July 18, 2015
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremiaAmélie Guihot, Chiara Dentone, Lambert Assoumou, et al.
AIDS (London, England)|February 27, 2015
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremiaLaure Campillo-Gimenez, Lambert Assoumou, Marc-Antoine Valantin, et al.
AIDS (London, England)|November 2, 2005
Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMVFrançois Boutboul, Denis Puthier, Victor Appay, et al.
The Journal of Antimicrobial Chemotherapy|November 17, 2015
Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)Lionel Piroth, Laetitia Moinot, Patrick Yeni, et al.
AIDS (London, England)|February 18, 2015
Increased carotid intima-media thickness is not associated with T-cell activation nor with cytomegalovirus in HIV-infected never-smoker patientsTiphaine Goulenok, Anders Boyd, Martin Larsen, et al.
Pageof 21

Showing results (111-120 of 201) with videos related to

Sort By:
Pageof 21
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2008
Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activationValérie Martinez, Marie-Claude Diemert, Martine Braibant, et al.
AIDS (London, England)|October 22, 2010
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patientsAna Canestri, Anne Krivine, Lambert Assoumou, et al.
AIDS (London, England)|April 8, 2009
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patientsAntoine Bénard, Florence Damond, Pauline Campa, et al.
AIDS (London, England)|May 12, 2017
Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individualsMorgane Griesbeck, Marc-Antoine Valantin, Karine Lacombe, et al.
AIDS Research and Human Retroviruses|October 14, 2020
A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected NonprogressorsMariama Sadjo Diallo, Assia Samri, Charlotte Charpentier, et al.
AIDS (London, England)|July 18, 2015
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremiaAmélie Guihot, Chiara Dentone, Lambert Assoumou, et al.
AIDS (London, England)|February 27, 2015
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremiaLaure Campillo-Gimenez, Lambert Assoumou, Marc-Antoine Valantin, et al.
AIDS (London, England)|November 2, 2005
Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMVFrançois Boutboul, Denis Puthier, Victor Appay, et al.
The Journal of Antimicrobial Chemotherapy|November 17, 2015
Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)Lionel Piroth, Laetitia Moinot, Patrick Yeni, et al.
AIDS (London, England)|February 18, 2015
Increased carotid intima-media thickness is not associated with T-cell activation nor with cytomegalovirus in HIV-infected never-smoker patientsTiphaine Goulenok, Anders Boyd, Martin Larsen, et al.
Pageof 21